Phase I, Open-label, Randomized, Two Part, Three-Period, Two-Sequence, Cross-over Study to Investigate the Relative Bioavailability of a Tablet Formulation Compared to Powder-in-Capsule of M7583 Including a Food Effect Evaluation for the Tablet in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2018
At a glance
- Drugs M 7583 (Primary)
- Indications B-cell lymphoma
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.
- 27 Oct 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 05 Oct 2017 New trial record